Singapore markets close in 6 hours 20 minutes

Straits Times Index
3,310.40
+2.50(+0.08%)
Nikkei
38,905.45
+288.35(+0.75%)
Hang Seng
18,820.39
-375.21(-1.95%)
FTSE 100
8,370.33
-46.12(-0.55%)
Bitcoin USD
69,463.32
-597.09(-0.85%)
CMC Crypto 200
1,513.00
-13.42(-0.88%)

Vera Therapeutics, Inc. (VERA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD

Add to watchlist

37.97

-1.79

(-4.50%)

At close: 04:00PM EDT

38.21

+0.24

(+0.63%)

After hours:

05:55PM EDT

Trade prices are not sourced from all markets

All

GlobeNewswire
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatmentTopline 96-week data from ORIGIN 2 trial expected in Q4 2024Pivotal Phase 3 ORIGIN 3 trial estimated to complete enrollment for primary endpoint in Q3 2024; topline data expected in 1H 2025Completed $287.5 million financing, further strengthening the Company’s balance sheet BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Vera The
GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 1, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 15,000 shares of Class A common stock and restricted stock units (RSUs) for 7,500 shares of Class A common stock to three new employees under Vera’s 2024 Inducement Plan (the Inducement Plan). Vera also announced that on May 6, 2024, the
Simply Wall St.
Vera Therapeutics, Inc.'s (NASDAQ:VERA) high institutional ownership speaks for itself as stock continues to impress, up 5.0% over last week
Key Insights Significantly high institutional ownership implies Vera Therapeutics' stock price is sensitive to their...